Prospective Study of White Blood Cells
NCT04838171 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2026-01-21
Summary
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
Conditions
- Autoimmune Diseases
- Inflammation
- Rejection; Transplant, Liver
Interventions
- OTHER
-
White blood cell and blood collection
Mononucleocytes will be collected via apheresis
Sponsors & Collaborators
-
Quell Therapeutics Limited
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-03-24
- Primary Completion
- 2029-12-31
- Completion
- 2030-01-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19
NCT04762186 ·Status: TERMINATED ·Phase: PHASE1
-
Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors
NCT03114566 ·Status: TERMINATED
-
Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
NCT04408950 ·Status: COMPLETED
-
Blood Sampling of Healthy Volunteers for Immunological Research
NCT03819829 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Immune Signaling Networks in Healthy Human Volunteers
NCT01882582 ·Status: COMPLETED
-
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
NCT04871165 ·Status: UNKNOWN
-
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
NCT05164016 ·Status: COMPLETED
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Understanding COVID-19 Vaccine Immunity in Tissue and Blood
NCT05682625 ·Status: WITHDRAWN
-
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
NCT04093622 ·Status: TERMINATED
-
Immune Cell Response to Stimuli
NCT00397280 ·Status: RECRUITING
-
Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients
NCT02739412 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia
NCT04578210 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Functional Characterization of CD8+ T Cells After Supramaximal Exercise
NCT06484101 ·Status: COMPLETED ·Phase: NA
-
In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients
NCT00001336 ·Status: COMPLETED
-
Third Party Viral Specific T-cells (VSTs)
NCT02532452 ·Status: RECRUITING ·Phase: PHASE2
-
Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History
NCT06821685 ·Status: RECRUITING ·Phase: PHASE1
-
Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer
NCT06131775 ·Status: RECRUITING ·Phase: NA
-
An Experimental Medicine Clinical Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis and Patients With Solid Tumours.
NCT05133128 ·Status: TERMINATED ·Phase: NA
-
Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
NCT06040918 ·Status: COMPLETED ·Phase: PHASE1
-
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
NCT04365101 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination
NCT02843321 ·Status: UNKNOWN ·Phase: PHASE1
-
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
NCT04362865 ·Status: COMPLETED
-
Adoptive Cell Transfer for the Immunotherapy of COVID-19 in Colombia
NCT04344548 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Immune Cell Therapy for Advanced Solid Tumors
NCT07260058 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2